GlassScriptPhysician profile
Edwin Parrilla
NPI 1710306642
$10,366.66
in general payments reported to CMS, 2019-2025
25 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,870 · 2020: $2,502 · 2021: $2,811 · 2022: $1,191 · 2023: $547 · 2024: $280 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,597.64 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $1,104.18 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Amgen INC. | $997.15 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $731.49 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $691.82 | 2019-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $656.84 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.99 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $450.67 | 2021-2025 | |
| Amarin Pharma, INC. | $420.13 | 2019-2022 | |
| Abbvie INC. | $324.46 | 2021 | |
| Merck Sharp & Dohme LLC | $300.91 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $288.89 | 2019-2023 | |
| Galderma Laboratories, L.P. | $262.36 | 2022-2023 | |
| Allergan, INC. | $246.69 | 2020-2021 | |
| Abbott Laboratories | $195.65 | 2021-2024 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $171.24 | 2020-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $110.73 | 2019 | |
| Jazz Pharmaceuticals INC. | $40.84 | 2021-2022 | |
| Horizon Therapeutics Plc | $32.29 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $23.49 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.54 | 2021 | |
| Corcept Therapeutics | $15.16 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2019 | |
| Cardiovascular Systems INC. | $13.75 | 2021 | |
| Merz North America, INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Parrilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.